Georgia SB 68 (2025): The Phantom Damages Rule and What It Means for Pharmacy Liens

James Wong — Founder & Pharmacist, LienScripts | February 22, 2026 | 9 min read

Georgia's Senate Bill 68, signed April 21, 2025, eliminated 'phantom damages' from personal injury cases under O.C.G.A. § 51-12-1.1 — limiting medical expense recovery to 'reasonable value' informed by what Medicare, Medicaid, and private insurers actually pay. For pharmacy liens, this creates a new damages battleground: how is 'reasonable value' determined when the prescription has no insurance equivalent?

Georgia SB 68: What Changed and Why

Georgia Senate Bill 68 was signed into law on April 21, 2025, and took immediate effect for cases filed on or after that date. The legislation was the centerpiece of a broader Georgia tort reform effort and drew intense opposition from the state's plaintiffs' bar and trial attorney associations.

The core provision — now codified at O.C.G.A. § 51-12-1.1 — eliminates what proponents called "phantom damages": the gap between what a medical provider bills for a service and what any real-world payer would actually pay for that service.

The Legislative Theory Behind "Phantom Damages"

Supporters of SB 68 argued that the prior system allowed plaintiffs to claim inflated medical damages because:

• Providers bill list prices that no insurer actually pays
• The difference between the billed amount and the insurer's negotiated rate is "phantom" — it was never at economic risk, never actually paid, and represents a windfall
• This inflation drives up settlement demands, insurance premiums, and litigation costs

Opponents argued that:

• Market billing rates are not arbitrary — they reflect the true cost of providing care to uninsured and underinsured patients
• Limiting recovery to government reimbursement rates ignores that Medicare/Medicaid rates are deliberately set below market to achieve government cost objectives
• Restricting access to pharmacy liens and letters of protection harms the uninsured and underinsured patients who most need them

Whether or not you agree with the legislative policy, the law is in effect. Georgia PI attorneys must now operate within this framework.

O.C.G.A. § 51-12-1.1: The Reasonable Value Standard

The Core Rule

O.C.G.A. § 51-12-1.1 establishes that in a personal injury case, recoverable medical expenses are limited to the "reasonable value of the medically necessary care" provided.

The Evidence Standard: Government Rates Are Admissible

The statute specifically makes admissible — as evidence of reasonable value — the following:

• Medicare rates for comparable services in the relevant geographic market
• Medicaid rates for comparable services in the relevant geographic market
• Private health insurer rates — what private insurers actually paid for comparable services
• Any other evidence a court determines to be relevant to the reasonable value determination

The statute does not cap medical damages at Medicare rates. It makes Medicare rates admissible evidence of reasonable value — meaning the defense can introduce Medicare rates as a floor or benchmark, and the jury decides where within the range of evidence "reasonable value" falls.

What the Defendant Must Do to Invoke This

The defendant bears the burden of introducing evidence of government or insurer rates if it wants the jury to consider them. The statute does not automatically apply a cap — it creates an evidentiary battleground where both sides can present market value evidence.

The Effective Date and Retroactivity

SB 68's reasonable value standard applies to cases filed on or after April 21, 2025. Cases filed before that date are governed by prior Georgia law, under which medical damages were measured by the full billed amount.

For pharmacy liens in cases filed before April 21, 2025: prior law applies. For cases filed after: O.C.G.A. § 51-12-1.1 applies.

For cases that were already pending with ongoing pharmacy lien treatment as of April 21, 2025, but not yet filed: confirm the filing date controls, not the accident date or treatment date.

What "Reasonable Value" Means for Pharmacy Liens

The Core Challenge

Pharmacy lien prescriptions are not typically covered by Medicare or Medicaid in the same way that office visits or procedures are. Many PI medications — compounded topicals, specialty pain management formulations, CGRP medications for post-traumatic migraine — are either:

1. Not covered by Medicare/Medicaid at all: No government rate exists as a benchmark
2. Covered by Medicare Part D at plan-negotiated rates, but in a complex way that varies by plan and formulary tier
3. Covered only at certain dosages or formulations under Medicare, while the prescribed formulation has no equivalent

When the defense cannot produce a Medicare or Medicaid benchmark for a specific medication, the statute still allows other market evidence. But the defense will argue that the existence of any insurer rate for any comparable formulation is sufficient to establish a ceiling.

Building the Reasonable Value Case for Pharmacy Liens

For Georgia PI attorneys managing pharmacy liens post-SB 68:

Step 1: Identify the specific medications prescribed. For each medication on the lien, determine whether a Medicare Part D equivalent exists.

Step 2: For medications with Medicare equivalents: Research the Part D formulary tier and co-pay structure. The Medicare rate is the defense's likely evidence; your evidence should include cash-pay market rates at independent pharmacies and the clinical rationale for the specific formulation prescribed rather than a lower-cost alternative.

Step 3: For medications without Medicare equivalents: The absence of a Medicare benchmark is a fact — document it. The "reasonable value" evidence should come from market comparables: what do cash-pay patients pay for this medication at comparable pharmacies in the same geographic area?

Step 4: Document individualized clinical necessity. The statute covers "medically necessary" care. A prescription that is individualized, clearly indicated by the patient's specific injuries, and prescriber-documented as to necessity is in a stronger position than a protocol-driven prescription with no clinical narrative.

Step 5: Retain pharmacy pricing expert if needed. In significant cases, a pharmacoeconomics expert who can testify to market value for lien-based prescriptions may be appropriate. The plaintiff has the right to introduce evidence of reasonable value just as the defendant does.

SB 68's Other Provisions

While the phantom damages rule is the most relevant provision for pharmacy liens, SB 68 included other reforms:

Punitive damages: Modified standards for punitive damage awards in certain case categories.

Case management reforms: Changes to discovery and case management scheduling.

Impact on pending cases: Cases filed before April 21, 2025 are unaffected by the reasonable value standard. Attorneys with pre-April 2025 cases should confirm that prior law applies to their full damages presentation.

Georgia and the National Tort Reform Pattern

SB 68 follows the same national template as Florida HB 837 (2023) and California's pending 2026 ballot initiative: limit medical expense recovery to what real-world payers actually pay, reducing the spread between billed amounts and economic reality.

Georgia's version is in some ways more precise than Florida's. Rather than a vague "amounts actually paid" standard (which raises questions about what that means for deferred-payment lien providers), Georgia's statute creates an evidentiary framework that lets both sides present market value evidence. This gives plaintiff attorneys more opportunity to establish the market value of lien-based care through affirmative evidence — rather than simply arguing that HB 837's "amounts actually paid" language doesn't apply to them.

Practical Protocol for Georgia PI Attorneys Post-SB 68

At intake (post-April 21, 2025 filings):

• Confirm the filing date (not accident date) to determine which law applies
• At pharmacy lien enrollment, begin building the market rate documentation file
• Document the patient's lack of insurance coverage and why lien-based pharmacy was the only viable access option

During treatment:

• Ensure treating physicians document individualized clinical rationale for each prescription
• Avoid protocol-driven prescribing patterns — the SB 68 battleground is "medical necessity" as well as "reasonable value"

At demand/litigation:

• For each lien prescription, present evidence of: (1) clinical necessity, (2) market cash-pay rate, (3) absence of Medicare equivalent or explanation of why the specific formulation differs from covered equivalents
• Be prepared for defense Medicare rate evidence and have affirmative rebuttal ready

Related Resources

• The Tort Reform Wave: FL, GA, and CA
• Florida HB 837 (2023): What It Means for Pharmacy Liens
• California's 2026 Ballot Initiative Would Eliminate Lien-Based Medical Care
• Georgia Pharmacy Lien Laws Explained
• What Is a Pharmacy Lien?

[!SOURCE] Georgia SB 68 — O.C.G.A. § 51-12-1.1 (2025) — Georgia's 2025 tort reform statute codifying the reasonable value standard for medical expense recovery and making government and insurer payment rates admissible as evidence.